De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

被引：0
|
作者：
Dennen, Syvart
Shao, Anran
Dennen, Syvart
Cockrum, Paul
Paluri, Ravi Kumar
机构：
[1] Genesis Res, Hoboken, NJ USA
[2] Ipsen Biopharmaceut Inc, Cambridge, MA USA
[3] Wake Forest Baptist Hlth, Winston Salem, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
130-544; 130-3426-5390-2622-5397; 613-135-244-3829-325-11291; 261-2394; 130-540-543-11341; 2; 1699; 239; 16; 193; 1692; 54; 1700; 8; 6; 4; 3;
D O I：
10.1200/JCO.2024.42.3_suppl.628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：628 / 628
页数：1
相关论文
共 50 条
  • [31] How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world
    Pretta, Andrea
    Spanu, Dario
    Mariani, Stefano
    Liscia, Nicole
    Ziranu, Pina
    Pusceddu, Valeria
    Puzzoni, Marco
    Massa, Elena
    Scartozzi, Mario
    Lai, Eleonora
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (05): : 417 - 422
  • [32] Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
    Kim, G.
    Surinach, A.
    Wang, S.
    Lamarre, N.
    Cockrum, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1107 - S1108
  • [33] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
    King, Gentry
    Ittershagen, Stacie
    He, Luyang
    Shen, Ying
    Li, Frank
    Villacorta, Reginald
    ADVANCES IN THERAPY, 2022, 39 (12) : 5433 - 5452
  • [34] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
    Gentry King
    Stacie Ittershagen
    Luyang He
    Ying Shen
    Frank Li
    Reginald Villacorta
    Advances in Therapy, 2022, 39 : 5433 - 5452
  • [35] Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
    Umpawan, N.
    Termsinsuk, P.
    Kaosombatwattana, U.
    Akewanlop, C.
    Korphaisarn, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S919 - S920
  • [36] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)
    Paluri, Ravi Kumar
    Silver, Michelle
    Cockrum, Paul
    Dennen, Syvart
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] REAL-WORLD IMPACT OF PRIOR SURGERY ON OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS
    George, B.
    Cockrum, P.
    Lamarre, N.
    Surinach, A.
    VALUE IN HEALTH, 2021, 24 : S21 - S21
  • [39] Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    George, Ben
    Kent, Matthew
    Surinach, Andy
    Lamarre, Neil
    Cockrum, Paul
    Chudnovsky, Aleksander
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan.
    Abushahin, Laith, I
    Cockrum, Paul
    Surinach, Andy
    Belanger, Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345